Search results
Americans with HIV are living longer. Federal spending isn’t keeping up
Detroit News· 1 day agoMalcolm Reid recently marked the anniversary of his HIV diagnosis on Facebook. “Diagnosed with HIV...
Philadelphia FIGHT’s HIV Education Summit will return for in-person June event
WHYY· 18 hours agoPhiladelphia FIGHT began as a grassroots advocacy group that championed the health rights of those...
Drugs that treat HIV trialled in people with multiple brain tumours
PA Media: Science via Yahoo News· 3 days agoDrugs that treat HIV are being trialled for the first time in people with multiple brain tumours,...
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
Zacks via Yahoo Finance· 3 days agoGilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool...
Column: Anthony Fauci has a right to savage Trump. His memoir takes a different and telling approach
Los Angeles Times Opinion via Yahoo News· 23 hours agoAs director of the National Institute of Allergy and Infectious Diseases, he was at the red hot...
Federal appeals court says some employers can exclude HIV prep from insurance coverage
WJET - WFXP Erie· 3 days agoNEW ORLEANS (AP) — Employers who challenged some federal health insurance requirements cannot be...
Community-based early HIV testing and treatment to manage and prevent emerging HIV among people who...
Medical Xpress· 7 days agoCommunity-based testing and treatment response to Glasgow's HIV outbreak among people who inject...
Old report about overseas Filipino workers with HIV falsely linked to Dubai
AFP via Yahoo News· 4 days agoA news report from 2011 about HIV infections among Philippine migrant workers has resurfaced in...
Appeals court finds 'Obamacare' pillar unconstitutional in suit over HIV-prevention drug
NBC NEWS· 3 days agoThe lawsuit centered on the objections of a coalition of small businesses in Texas to the...
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for ...
Morningstar· 4 days agoGilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable < ...